CAJ | 학술논문

目的：探讨全脑放疗联合伊立替康（CPT-11）治疗非小细胞肺癌（NSCLC）脑转移的剂量限制性毒性（ DLT）、最大耐受剂量（ MTD）及其临床疗效。方法选取2009年10月-2012年11月南昌大学第一附属医院肿瘤科经病理或细胞学证实的晚期NSCLC脑转移患者27例，采用全脑放疗联合CPT-11治疗，每周一至周五行全脑常规分割放疗，全脑剂量40 Gy/20次，分次剂量2 Gy；放射治疗的第1周开始应用CPT-11，每周六用药1次，共治疗4周。 CPT-11分6个剂量组：25 mg/m2组，50 mg/m2组，65 mg/m2组，80 mg/m2组，100 mg/m2组，120 mg/m2组。每个试验组至少入选3例患者，如在前一个剂量水平中患者无明显毒副作用则进入下一个剂量组，直至达到MTD。结果27例患者均完成治疗，可评价疗效，3例完全缓解（CR），17例部分缓解（PR），7例无变化（SD），总有效率为74.1％（20/27）。 DLT为白细胞计数下降、血小板计数下降及腹泻。试验得出MTD为100 mg/m2。结论全脑放疗联合CPT-11治疗NSCLC脑转移推荐Ⅱ期临床剂量为80 mg/m2。
목적：탐토전뇌방료연합이립체강（CPT-11）치료비소세포폐암（NSCLC）뇌전이적제량한제성독성（ DLT）、최대내수제량（ MTD）급기림상료효。방법선취2009년10월-2012년11월남창대학제일부속의원종류과경병리혹세포학증실적만기NSCLC뇌전이환자27례，채용전뇌방료연합CPT-11치료，매주일지주오행전뇌상규분할방료，전뇌제량40 Gy/20차，분차제량2 Gy；방사치료적제1주개시응용CPT-11，매주륙용약1차，공치료4주。 CPT-11분6개제량조：25 mg/m2조，50 mg/m2조，65 mg/m2조，80 mg/m2조，100 mg/m2조，120 mg/m2조。매개시험조지소입선3례환자，여재전일개제량수평중환자무명현독부작용칙진입하일개제량조，직지체도MTD。결과27례환자균완성치료，가평개료효，3례완전완해（CR），17례부분완해（PR），7례무변화（SD），총유효솔위74.1％（20/27）。 DLT위백세포계수하강、혈소판계수하강급복사。시험득출MTD위100 mg/m2。결론전뇌방료연합CPT-11치료NSCLC뇌전이추천Ⅱ기림상제량위80 mg/m2。
ObjectiveTodeterminethedose-limitingtoxicities(DLT),maximumtolerateddose(MTD)andclini-cal effect of CPT-11 combined with whole brain radiotherapy ( WBRT) for patients with brain metastases of non -small cell lung cancer(NSCLC).Methods 27withpathologicallyorcytologicallyconfirmedmetastasesofNSCLCadmittedtoDepartmentof Oncology of the First Affiliated Hospital of Nanchang University from October 2009 to November 2012 were treated with WBRT and CPT-11.The patients were given fractionated radiotherapy from every Monday to Friday , with daily fraction of 2 Gy per week and a total radiation dose of 40 Gy.CPT -11 was given at the first week , with the drug administered every Saturday for four weeks.The dose of CPT-11 was categorized into six groups: 25 mg/m2 group, 50 mg/m2 group, 65 mg/m2 group, 80 mg/m2 group, 100 mg/m2 group and 120 mg/m2 group.Each group had at least 3 cases, and the dose of CPT-11 would be increased to the next level if it was safe with the lower level until it reached MTD .Results All 27 cases completed the treatment and could be evaluated in terms of clinical effect .3 cases had complete remission , 17 cases had partial remission and 7 cases had no significant difference, and the total effect was 74.1%(20/27) .DLT was the decreasing of white blood cell count and blood platelet count , as well as diarrhea.The MTD was 100 mg/m2.Conclusion The dose for phase Ⅱis 80 mg/m2 in the treatment of patients with brain metastases of NSCLC with WBRT combined with CPT -11.